Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Fineline Cube Jul 10, 2026
Company Deals

Eyebright Medical Technology Plans GRD Listing on SIX Exchange to Raise RMB 1.4 Billion

Fineline Cube Aug 18, 2023

Eyebright Medical Technology Co., Ltd (SHA: 688050), a Beijing-based company specializing in ophthalmic medical devices,...

Company Drug

GC Biopharma Presents Data Showing Higher Thrombotic Risk with Roche’s Hemlibra

Fineline Cube Aug 18, 2023

South Korea’s GC Biopharma (KRX: 006280) has presented evidence suggesting that Roche’s (SWX: ROG) hemophilia...

Company Drug

Moderna Announces Immunogenicity of Updated COVID-19 Vaccine Against New Variants

Fineline Cube Aug 18, 2023

Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2...

Company

Tigermed Establishes International Headquarters in Hong Kong to Accelerate Global Expansion

Fineline Cube Aug 18, 2023

China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the opening of...

Company Medical Device

NMPA Approves Rapid Medical Ltd’s Intracranial Thrombectomy Stent for Marketing

Fineline Cube Aug 18, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Rapid Medical Ltd for...

Company Drug

Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug

Fineline Cube Aug 18, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...

Company Deals

CytoMed Therapeutics Partners with CNK Therapeutics for CAR Gene Grafting Technology

Fineline Cube Aug 18, 2023

Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a...

Company Drug

CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study

Fineline Cube Aug 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...

Company

Aurisco Pharmaceutical Passes US FDA cGMP Inspection at Jiangsu Plant

Fineline Cube Aug 17, 2023

China-based Aurisco Pharmaceutical (SHA: 605116) has announced the successful completion of a current Good Manufacturing...

Company Deals

Formosa Pharmaceuticals and Eyenovia Inc. Sign Licensing Deal for Ocular Surgery Treatment

Fineline Cube Aug 17, 2023

Taiwan’s Formosa Pharmaceuticals (TPE: 6838) and US-based Eyenovia Inc., (NASDAQ: EYEN) have signed their second...

Company

Biocytogen Pharmaceuticals Opens US Subsidiary Biocytogen Boston Corp. in Massachusetts

Fineline Cube Aug 17, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations...

Company Drug

CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia

Fineline Cube Aug 17, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...

Company Drug

Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment

Fineline Cube Aug 17, 2023

China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from...

Company Drug

European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults

Fineline Cube Aug 17, 2023

The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...

Company Drug

BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC

Fineline Cube Aug 17, 2023

Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...

Company Drug

Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA

Fineline Cube Aug 17, 2023

Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...

Company Drug

Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer

Fineline Cube Aug 17, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Company Deals

Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform

Fineline Cube Aug 17, 2023

US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...

Company Digital

JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report

Fineline Cube Aug 17, 2023

JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...

Company

Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law

Fineline Cube Aug 17, 2023

Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...

Posts pagination

1 … 514 515 516 … 693

Recent updates

  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
  • Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma
  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.